Heart transplantation in a patient with heteroresistant vancomycin-intermediate Staphylococcus aureus ventricular assist device mediastinitis and bacteremia

Transplant Infectious Disease

Volumn 15, Issue 5, 2013, Pages

  Swartz, T H ^a   Huprikar, S ^a   Labombardi, V ^b   Pinney, S ^a   Anyanwu, A ^a   Lee, M ^a   Patel, G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK HOSPITAL QUEENS   (United States)

Author keywords

hVISA VISA; MRSA; Orthotopic heart transplantation; Staphylococcus aureus; Telavancin resistance

Indexed keywords

ACETYLSALICYLIC ACID; CARVEDILOL; COTRIMOXAZOLE; DAPTOMYCIN; FUROSEMIDE; LINEZOLID; LISINOPRIL; PREDNISONE; TACROLIMUS; TELAVANCIN; VANCOMYCIN; WARFARIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ABSCESS; ADULT; ANTIBIOTIC THERAPY; ARTICLE; AUTOPSY; BACTEREMIA; BLOOD CULTURE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE CARDIOMYOPATHY; CREATININE CLEARANCE; DEBRIDEMENT; DEFIBRILLATOR; DEVICE INFECTION; DEVICE REMOVAL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FEVER; HEART TRANSPLANTATION; HEMOPERITONEUM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LEFT VENTRICULAR ASSIST DEVICE; LEUKOCYTOSIS; MALAISE; MEDIASTINITIS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; SUPPURATION; TACHYCARDIA; THORAX PAIN; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT FAILURE; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; ADVERSE EFFECTS; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; HEART ASSIST DEVICE; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; ISOLATION AND PURIFICATION; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; DEBRIDEMENT; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; MEDIASTINITIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84884990141     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12123     Document Type: Article

References (14)

1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-292.
2. Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 2011; 66: 1057-1060.
3. Joson J, Grover C, Downer C, Pujar T, Heidari A. Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure. J Antimicrob Chemother 2011; 66: 2186-2188.
4. Marcos LA, Camins BC. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. Antimicrobl Agents Chemother 2010; 54: 5376-5378.
5. Nace H, Lorber B. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin. J Antimicrob Chemother 2010; 65: 1315-1316.
6. Levy DT, Steed ME, Rybak MJ, et al. Successful treatment of a left ventricular assist device infection with daptomycin non-susceptible methicillin-resistant Staphylococcus aureus: case report and review of the literature. Transpl Infect Dis 2012; 14: E89-E96.
7. CLSI. Clinical Laboratory and Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. Wayne, PA, USA: Clinical Laboratory Standards Institute, 2010.
8. ™ (televancin for injection) package insert, 2008. Available at http://www.vibativ.com.
9. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54: 755-771.
10. Satola SW, Farley MM, Anderson KF, Patel JB. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol 2011; 49: 177-183.
11. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-1082.
12. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340: 517-523.
13. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 1177-1184.
14. Kosowska-Shick K, Clark C, Pankuch GA, et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob Agents Chemother 2009; 53: 4217-4224.